Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer Article

Industry Collaboration International Collaboration

cited authors

  • Mutch, David; Voulgari, Athina; Chen, Xian (Marissa); Bradley, William H.; Oaknin, Ana; Perez Fidalgo, Jose Alejandro; Montosa, Fernando Galvez; Herraez, Antonio Casado; Holloway, Robert W.; Powell, Matthew A.; Nowicka, Malgorzata; Schaefer, Gabriele; Merchant, Mark; Yan, Yibing

authors

Publication Date

  • January 30, 2024

webpage

published in

category

keywords

  • MEK inhibitor
  • MKNK1
  • NF1
  • PARP inhibitor
  • immune checkpoint blockade
  • ovarian cancer

start page

  • 1940

end page

  • 1951

volume

  • 130

issue

  • 11